BioMarin Pharmaceutical Inc. (BMRN) Q1 2024 Earnings: Surpasses Revenue and EPS Estimates

GuruFocus Research

April 24, 2024 at 5:33 p.m.·3 min read

Revenue: Reported at $648.8 million, marking a 9% increase year-over-year, slightly below the estimated $651.79 million.
Net Income: GAAP net income surged to $88.7 million, a substantial 74% increase from the previous year, significantly exceeding the estimated $62.56 million.
Earnings Per Share (EPS): GAAP diluted EPS reached $0.46, up 70% year-over-year, surpassing the estimated $0.35.
Non-GAAP Performance: Non-GAAP diluted EPS reported at $0.71, an 18% increase year-over-year, indicating strong profitability excluding specific expenses.
Product Performance: VOXZOGO revenue soared by 74% to $152.9 million, driven by a significant increase in the number of children treated.
Research and Development: Focused investment in high-value programs, with increased R&D expenses supporting new indications for VOXZOGO and other key assets.
Full-Year Guidance: Reaffirmed total revenue expectations and raised non-GAAP operating margin and EPS forecasts, reflecting confidence in continued growth and operational efficiency.

Warning! GuruFocus has detected 3 Warning Sign with BMRN.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released its 8-K filing on April 24, 2024, revealing a robust financial performance for the first quarter of 2024. The company reported total revenues of $648.8 million, a 9% increase year-over-year, which surpassed the analyst's expectation of $651.79 million. Notably, GAAP diluted earnings per share (EPS) stood at $0.46, a significant 70% increase from the previous year, and non-GAAP diluted EPS was $0.71, up 18% year-over-year, both exceeding the estimated earnings per share of $0.35.

Company Overview

BioMarin Pharmaceutical Inc. is renowned for its pioneering biotechnological innovations, particularly in the treatment of rare genetic diseases. The company's product portfolio includes several key treatments such as Naglazyme, Vimizim, and Brineura, as well as Kuvan and Palynziq for the rare metabolic disorder PKU. BioMarin has also made significant strides with its newest treatments, Voxzogo for achondroplasia, approved in 2021, and Roctavian for hemophilia A gene therapy, approved in Europe in 2022 and in the US in 2023.

Financial and Operational Highlights

The first quarter results were significantly bolstered by the increased sales of VOXZOGO, which saw a remarkable 74% increase in net product revenues, amounting to $152.9 million. The treatment's success is attributed to the growing number of children receiving the therapy, with over 3,100 beneficiaries across 43 active markets by the quarter's end. This represents a 102% increase in the number of children treated year-over-year.

Despite challenges from generic competition impacting KUVAN revenues, which declined by 29%, and a decrease in NAGLAZYME product revenues due to order timing in the Middle East, the company's overall revenue growth remained strong. This growth is a testament to BioMarin's effective strategy and operational execution, particularly in maximizing and accelerating the reach of VOXZOGO.

Strategic R&D Initiatives and Future Outlook

BioMarin's strategic focus on research and development has led to the prioritization and acceleration of its three highest-value programs, aiming to enhance patient impact and shareholder value. The company reaffirmed its full-year 2024 guidance for total revenues and raised its projections for non-GAAP operating margin and non-GAAP EPS, reflecting a positive outlook for the remainder of the year.

Furthermore, the company's ongoing discussions with health authorities regarding VOXZOGO for additional indications, such as hypochondroplasia and idiopathic short stature, are progressing well, with clinical trials expected to commence later this year.

Conclusion

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)'s first quarter of 2024 demonstrates a strong trajectory with significant revenue growth and profitability, primarily driven by the successful expansion of VOXZOGO and strategic R&D efforts. As the company continues to navigate the complexities of the biotechnology industry, its focus on innovative therapies and operational excellence positions it well for sustained growth and value creation.

For detailed financial figures and further information, refer to the full 8-K filing and join the upcoming webcast to discuss these results.

Explore the complete 8-K earnings release (here) from Biomarin Pharmaceutical Inc for further details.

This article first appeared on GuruFocus.

Barrons.com
DJT Stock Falls. SEC Charges Trump Media Auditing Firm With ‘Massive Fraud.’
The SEC charges the company’s auditing firm BF Borgers CPA and its owner Benjamin Borgers with ‘massive fraud.’
The Canadian Press
TD worst-case scenario more likely after drug money laundering allegations: analyst
TORONTO — TD Bank Group could be hit with more severe penalties than previously expected, says a banking analyst, after a report that the investigation it faces in the U.S. is tied to laundering illicit fentanyl profits. National Bank analyst Gabriel Dechaine said in a note that the worst-case scenario of the multiple U.S. investigations TD faces needs reassessing after the Wall Street Journal reported the link on Thursday. The newspaper said the U.S. Justice Department investigation is focused
GOBankingRates
Kevin O’Leary: The Money Is ‘Not in Bitcoin’ — Here’s What You Should Invest In
Cash flow. If you're a fan of "Shark Tank" or follow Kevin O'Leary, you've likely heard him talk about the importance of cash flow. In a recent video he posted to LinkedIn, O'Leary spoke again about...
Reuters
US stands to lose Canadian natural gas when LNG Canada terminal starts up
The start-up of LNG Canada, the country's first such export terminal, is likely to strain its natural gas supplies for multiple years and force producers to reduce exports to the U.S., where demand for the fuel is record high, companies said. Shell-led LNG Canada has begun testing its C$40-billion British Columbia terminal ahead of commercial operations starting in mid-2025. The terminal will process up to 2 billion cubic feet per day (bcfd), representing 11% of current Canadian gas output.
Yahoo Finance Canada
Galen Weston calls Loblaw boycott 'misguided criticism', says grocer not responsible for higher prices
"Their frustration is understandable, but this kind of expectation betrays a misunderstanding of what's actually driving food prices higher in this country."
The Independent
Accounting firm used by Trump Media hit with ‘massive fraud’ charge
Fraud alleged to have impacted upwards of 500 public companies, according to Securities and Exchange Commission
Financial Post
Posthaste: Capital gains tax hike will hit more Canadians than we thought
Analysts say higher tax will cut returns from Canadian stocks
The Canadian Press
TD Bank hit with $9.2M penalty after failing to report suspicious transactions
TORONTO — Canada’s financial-crime watchdog has levied a $9.2-million penalty against The Toronto-Dominion Bank for non-compliance with money laundering and terrorist financing measures as the bank also faces compliance investigations in the U.S. The penalty by the Financial Transactions and Reports Analysis Centre of Canada, or Fintrac, comes after it imposed a $7.5-million fine against RBC and a $1.3-million fine against CIBC, both of which were announced in December. Those penalties were also
Yahoo Finance Canada
Air Canada shares plunge as wider loss, slowing travel demand weigh
The Montreal-based airline reported an adjusted net loss of $96 million, or 27 cents per share, more than the seven cents per share loss that analysts had expected.
The Motley Fool
Monthly Income Masters: 2 Canadian Stocks Paying Steady Dividends Every 30 Days
You can expect to earn reliable monthly passive income for years to come by investing in these two top Canadian monthly dividend stocks now. The post Monthly Income Masters: 2 Canadian Stocks Paying Steady Dividends Every 30 Days appeared first on The Motley Fool Canada.
The Canadian Press
There's a limit to how much interest rates in Canada and U.S. can diverge: Macklem
Bank of Canada governor Tiff Macklem says Canadian interest rates don't have to match U.S. or global rates, but there is a limit to how much they can diverge. Macklem made the comments while testifying before the House of Commons finance committee today. The governor says Canada is nowhere close to the limit when it comes to how much Canadian and American interest rates can differ. The Bank of Canada is widely expected to begin lowering its policy rate in the coming months, while forecasters exp
Reuters
Canadian dollar forecasts trimmed by analysts as BoC moves closer to rate cuts: Reuters poll
The Canadian dollar is set to strengthen less than previously expected over the coming year as the Bank of Canada makes progress on taming inflation and will likely begin cutting interest rates ahead of the Federal Reserve, a Reuters poll found. According to the median forecast of nearly 40 foreign exchange analysts in the April 29-May 2 poll, the loonie will strengthen 0.7% to 1.36 per U.S. dollar, or 73.53 U.S. cents, in three months, compared to 1.34 in last month's poll. "In the near term, I think there are going to be some headwinds," said Bipan Rai, global head of FX strategy at CIBC Capital Markets.
Simply Wall St.
Cenovus Energy Inc. Just Beat EPS By 36%: Here's What Analysts Think Will Happen Next
Cenovus Energy Inc. ( TSE:CVE ) investors will be delighted, with the company turning in some strong numbers with its...
The Motley Fool
How Much Will Bank of Nova Scotia Pay in Dividends This Year?
Bank of Nova Scotia (TSX:BNS) stock has a 6.66% dividend yield. The post How Much Will Bank of Nova Scotia Pay in Dividends This Year? appeared first on The Motley Fool Canada.
Financial Post
David Rosenberg: Why the Bank of Canada needs to start cutting rates … Now
Key data points indicate the central bank is keeping policy 'far too tight'
Yahoo Finance Canada
Weak loonie? These TSX stocks could gain strength, says RBC
It says Canadian stocks that tend to generate more earnings from the U.S. span the technology, media, financial, healthcare, industrial, and forest product sectors.
Business Insider
There are 4 big factors to watch that could bring turmoil to financial markets, research firm says
There is plenty of scope for material worsening of financial conditions if the macro and geopolitical outlooks deteriorate, Capital Economics said.
The Canadian Press
Air Canada pins hopes on business travellers after profits fall
MONTREAL — Canadian airlines have enjoyed a two-year boom amid consumer hunger for post-pandemic travel. But as that pent-up demand recedes, the country's largest carrier hopes to ramp up ticket sales to corporate customers instead. Until recently, the travel surge that followed COVID-19 restrictions failed to reach the business world, where pandemic habits of video conferencing and remote work proved tough to shake. But Air Canada, which reported a first-quarter earnings loss on Thursday — and
The Motley Fool
3 TSX Stocks to Buy as Oil Prices Rise
Given their solid underlying businesses and healthy growth prospects, these three TSX stocks are ideal buys in this volatile environment. The post 3 TSX Stocks to Buy as Oil Prices Rise appeared first on The Motley Fool Canada.
The Motley Fool
It’s Currently 8.7%, but Is BCE’s Dividend Safe?
BCE stock recently dipped, and it pays an ultra high dividend. But investors might want to think twice before jumping in. The post It’s Currently 8.7%, but Is BCE’s Dividend Safe? appeared first on The Motley Fool Canada.

S&P/TSX

S&P 500

DOW

CAD/USD

CRUDE OIL

Bitcoin CAD

CMC Crypto 200

GOLD FUTURES

RUSSELL 2000

10-Yr Bond

NASDAQ

VOLATILITY

FTSE

NIKKEI 225

CAD/EUR

Company Overview

Financial and Operational Highlights

Strategic R&D Initiatives and Future Outlook

Conclusion

Latest Stories